Patents by Inventor Peter Eamon Molloy

Peter Eamon Molloy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HIGH AFFINITY NY-ESO T CELL RECEPTORS
    Publication number: 20170088599
    Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.
    Type: Application
    Filed: October 12, 2016
    Publication date: March 30, 2017
    Inventors: Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
  • TCR LIBRARIES
    Publication number: 20170051036
    Abstract: The present invention relates to a library of particles, the library displaying a plurality of different T cell receptors (TCRs), wherein the plurality of TCRs may consist essentially of TCRs which may comprise an alpha chain variable domain from a natural repertoire and a beta chain variable domain from a natural repertoire, wherein the alpha chain variable domain may comprise a TRAV12-2 or a TRAV21 gene product and the beta chain variable domain may comprise a TRBV6 gene product.
    Type: Application
    Filed: September 12, 2016
    Publication date: February 23, 2017
    Inventors: Bent Karsten JAKOBSEN, Peter Eamon MOLLOY, Annelise Brigitte VUIDEPOT, Nathaniel Ross LIDDY
  • High affinity NY-ESO T cell receptors
    Patent number: 9512197
    Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumor cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: December 6, 2016
    Assignee: ADAPTIMMUNE LIMITED
    Inventors: Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
  • T cell receptor display
    Patent number: 9447410
    Abstract: A proteinaceous particle, for example a bacteriophage, ribosome or cell, displaying on its surface a T-cell receptor (TCR). The displayed TCR is preferably a heterodimer having a non-native disulfide bond between constant domain residues. Such display particles may be used for the creation of diverse TCR libraries for the identification of high affinity TCRs. Several high affinities are disclosed.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: September 20, 2016
    Assignees: ADAPTIMMUNE LIMITED, IMMUNOCORE LIMITED
    Inventors: Bent Karsten Jakobsen, Peter Eamon Molloy, Yi Li, Jonathan Michael Boulter
  • HIGH AFFINITY NY-ESO T CELL RECEPTORS
    Publication number: 20160159881
    Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.
    Type: Application
    Filed: December 14, 2015
    Publication date: June 9, 2016
    Inventors: Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
  • T cell receptor display
    Patent number: 9279122
    Abstract: A proteinaceous particle, for example a bacteriophage, ribosome or cell, displaying on its surface a T-cell receptor (TCR). The displayed TCR is preferably a heterodimer having a non-native disulfide bond between constant domain residues. Such display particles may be used for the creation of diverse TCR libraries for the identification of high affinity TCRs. Several high affinities are disclosed.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: March 8, 2016
    Assignees: ADAPTIMMUNE LIMITED, IMMUNOCORE LIMITED
    Inventors: Bent Karsten Jakobsen, Peter Eamon Molloy, Yi Li
  • High affinity HIV T cell receptors
    Patent number: 9255135
    Abstract: The present invention provides TCRs having high affinity. The TCR binds to SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 with a KD of less than or equal to 1 ?M and/or an off-rate (koff) of 1×10?3 S?1 or slower using Surface Plasmon Resonance. The TCRs are non-native, isolated or recombinant. The TCRs are useful, either alone, or with a therapeutic agent, for targeting HIV infected cells that present the SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 complex.
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: February 9, 2016
    Assignees: Immunocore Limited, Adaptimmune Limited
    Inventors: Bent Karsten Jakobsen, Yi Li, Steven Mark Dunn, Peter Eamon Molloy
  • High affinity NY-ESO T cell receptors
    Patent number: 9156903
    Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumor cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: October 13, 2015
    Assignee: ADAPTIMMUNE LIMITED
    Inventors: Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
  • HIGH AFFINITY NY-ESO T CELL RECEPTORS
    Publication number: 20150231202
    Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.
    Type: Application
    Filed: April 17, 2015
    Publication date: August 20, 2015
    Inventors: Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Michael Dunn
  • T CELL RECEPTOR DISPLAY
    Publication number: 20140371085
    Abstract: A proteinaceous particle, for example a bacteriophage, ribosome or cell, displaying on its surface a T-cell receptor (TCR). The displayed TCR is preferably a heterodimer having a non-native disulfide bond between constant domain residues. Such display particles may be used for the creation of diverse TCR libraries for the identification of high affinity TCRs. Several high affinities are disclosed.
    Type: Application
    Filed: April 9, 2014
    Publication date: December 18, 2014
    Applicants: ADAPTIMMUNE LIMITED, IMMUNOCORE LIMITED
    Inventors: Bent Karsten Jakobsen, Torben Bent Andersen, Peter Eamon Molloy, Yi Li
  • T CELL RECEPTOR DISPLAY
    Publication number: 20140349855
    Abstract: A proteinaceous particle, for example a bacteriophage, ribosome or cell, displaying on its surface a T-cell receptor (TCR). The displayed TCR is preferably a heterodimer having a non-native disulfide bond between constant domain residues. Such display particles may be used for the creation of diverse TCR libraries for the identification of high affinity TCRs. Several high affinities are disclosed.
    Type: Application
    Filed: April 10, 2014
    Publication date: November 27, 2014
    Applicants: ADAPTIMMUNE LIMITED, IMMUNOCORE LIMITED
    Inventors: Bent Karsten Jakobsen, Torben Bent Andersen, Peter Eamon Molloy, Yi Li
  • T cell receptor display
    Patent number: 8741814
    Abstract: A proteinaceous particle, for example a bacteriophage, ribosome or cell, displaying on its surface a T-cell receptor (TCR). The displayed TCR is preferably a heterodimer having a non-native disulfide bond between constant domain residues. Such display particles may be used for the creation of diverse TCR libraries for the identification of high affinity TCRs. Several high affinities are disclosed.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: June 3, 2014
    Assignees: Immunocore Limited, Adaptimmune Limited
    Inventors: Bent Karsten Jakobsen, Torben Bent Andersen, Peter Eamon Molloy, Yi Li, Jonathan Michael Boulter
  • HIGH AFFINITY HIV T CELL RECEPTORS
    Publication number: 20130295063
    Abstract: The present invention provides TCRs having high affinity. The TCR binds to SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 with a KD of less than or equal to 1 ?M and/or an off-rate (koff) of 1×10?3 S?1 or slower using Surface Plasmon Resonance. The TCRs are non-native, isolated or recombinant. The TCRs are useful, either alone, or with a therapeutic agent, for targeting HIV infected cells that present the SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 complex.
    Type: Application
    Filed: January 3, 2013
    Publication date: November 7, 2013
    Inventors: Bent K. Jakobsen, Yi Li, Steven Mark Dunn, Peter Eamon Molloy
  • HIGH AFFINITY NY-ESO T CELL RECEPTORS
    Publication number: 20130058908
    Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.
    Type: Application
    Filed: March 26, 2012
    Publication date: March 7, 2013
    Inventors: Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
  • High affinity HIV T cell receptors
    Patent number: 8378074
    Abstract: The present invention provides TCRs having high affinity. The TCR binds to SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 with a KD of less than or equal to 1 ?M and/or an off-rate (koff) of 1×10?3 S?1 or slower using Surface Plasmon Resonance. The TCRs are non-native, isolated or recombinant. The TCRs are useful, either alone, or with a therapeutic agent, for targeting HIV infected cells that present the SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 complex.
    Type: Grant
    Filed: March 29, 2006
    Date of Patent: February 19, 2013
    Assignee: Immunocore Limited
    Inventors: Bent Karsten Jakobsen, Yi Li, Steven Mark Dunn, Peter Eamon Molloy
  • High affinity NY-ESO T cell receptors
    Patent number: 8367804
    Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.
    Type: Grant
    Filed: July 5, 2011
    Date of Patent: February 5, 2013
    Assignee: Immunocore Limited
    Inventors: Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn, Lucy Boulter
  • High affinity NY-ESO T cell receptor
    Patent number: 8143376
    Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC (SEQ ID NO:126) peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.
    Type: Grant
    Filed: May 18, 2005
    Date of Patent: March 27, 2012
    Assignee: Immunocore Limited
    Inventors: Jonathan Michael Boulter, Lucy Boulter, legal representative, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
  • HIGH AFFINITY NY-ESO T CELL RECEPTORS
    Publication number: 20110262414
    Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said that peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.
    Type: Application
    Filed: July 5, 2011
    Publication date: October 27, 2011
    Applicant: IMMUNOCORE LIMITED
    Inventors: Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn, Lucy Boulter
  • High affinity NY-ESO T cell receptors
    Patent number: 8008438
    Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC (SEQ ID NO:126)-HLA-A*0201, the SLLMWITQC (SEQ ID NO:126) peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumor cells. The TCRs have a KD for the said that peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.
    Type: Grant
    Filed: August 11, 2010
    Date of Patent: August 30, 2011
    Assignee: Immunocore Limited
    Inventors: Jonathan Michael Boulter, Lucy Boulter, legal representative, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
  • High affinity ny-eso t cell receptor
    Publication number: 20110038842
    Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said that peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.
    Type: Application
    Filed: May 18, 2005
    Publication date: February 17, 2011
    Applicant: AVIDEX LIMITED
    Inventors: Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn